While the underlying mechanisms by which imatinib sensitivity are lost are not entirely understood, it has been reported that 90-point mutations within the BCR-ABL protein comprise the majority of imatinib-resistant CML cases [2]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.